Receptor subtype abundance as a tool for effective intracellular signalling

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 1, 2008, Pages 66-79

  Mysliveček, Jaromír ^a   Nováková, Martina ^a   Klein, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adrenoceptors; G protein coupled receptor regulation; Heart; Muscarinic receptors

Indexed keywords

11 [[4 [4 (DIETHYLAMINO)BUTYL] 1 PIPERIDYL]ACETYL] 5,11 DIHYDRO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPIN 6 ONE; 3,6A,11,14 TETRAHYDRO 9 METHOXY 2 METHYL 12H ISOQUINO[1,2 B]PYRROLO[3,2 F][1,3]BENZOXAZINE 1 CARBOXYLIC ACID ETHYL ESTER; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BIPERIDEN; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR; HIMBACINE; METHOCTRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; OTENZEPAD; PIRENZEPINE; TRIPITRAMINE; TROPICAMIDE;

CARDIOVASCULAR AUTOREGULATION; DIMERIZATION; DRUG MECHANISM; ENZYME ACTIVITY; HEART FUNCTION; HEART PROTECTION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; HEART; PHYSIOLOGY;

ANIMALS; HEART; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION;

EID: 43649104637     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908783884939     Document Type: Review

References (127)

1. Brodde, O.E.; Michel, M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol. Rev., 1999, 51, 651-688.
2. Gauthier, C.; Langin, D.; Balligand, J.L. β3-adrenoceptors in the cardiovascular system. Trends Pharmacol. Sci., 2000, 21, 426-431.
3. Gauthier, C.; Leblais, V.; Kobzik, L.; Trochu, J.N.; Khandoudi, N. Bril, A.; Balligand, J.L.; Le Marec, H. (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J. Clin. Invest., 1998, 102, 1377-1384.
4. Tavernier, G.; Jimenez, M.; Giacobino, J.P; Hulo, N.; Lafontan, M.; Muzzin, P.; Langin, D. Norepinephrine Induces Lipolysis in β1/ β2/β3-adrenoceptor Knockout Mice. Mol. Pharmacol., 2005, 68, 793-739.
5. Berkowitz, D.E.; Price, D.T.; Bello, E.A.; Page, S.O.; Schwinn, D.A. Localization of messenger RNA for three distinct α2-adrenergic receptor subtypes in human tissues: Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology, 1994, 81, 1235-1244.
6. Kaumann, A.J.; Engelhardt, S.; Hein, L.; Molenaar, P.; Lohse, M. Abolition of (-)CGP 12177-evoked cardiostimulation in double β1/ β2-adrenoceptor knockout mice. Obligatory role of β1-adrenoceptors for putative β4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch. Pharmacol., 2001, 363, 87-93.
7. Santos, I.N.; Sumitame, M.; Caceres, V.M.; Moreira, M.F.; Krieger, M.H.; Spadari-Bratfisch, R.C. Evidence for two atypical conformations of beta-adrenoceptors and their interaction with Gi proteins. Eur. J. Pharmacol., 2005, 513, 109-118.
8. Ford, A.P.; Daniels, D.V.; Chang, D.J.; Gever, J.R.; Jasper, J.R., Lesnick, J.D.; Clarke, D.E. Pharmacological pleiotropism of the human recombinant alpha1 A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br. J. Pharmacol., 1997 121, 1127-1135.
9. Zimmer, H. G. Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression. J. Mol. Med., 1997, 75, 849-859.
10. Endoh, M.; Hiramoto, T.; Ishihata, A.; Takanashi, M.; Inui, J. Myocardial alpha1-adrenoceptors mediate positive inotropic effect and changes in phosphatidylinositol metabolism: Species differences in receptor distribution and the intracellular coupling process in mammalian ventricular myocardium. Circ. Res., 1991, 68, 1179-1190.
11. Kaumann, A.J.; Molenaar, P. Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn Schmiedebergs Arch. Pharmacol., 1997, 355, 667-681.
12. Zheng, M.; Han, Q.D.; Xiao, R.P. Distinct β-adrenergic receptor subtype signaling in the heart and their pathophysiological relevance. Acta Physiol. Sinica, 2004, 56, 1-15.
13. Ecker, P.M.; Lin, C.C.; Powers, J.; Kobilka, B.K.; Dubin, A.M.; Bernstein, D. Effect of targeted deletions of β1- and β2-adrenergic-receptor subtypes on heart rate variability Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H192-H199.
14. Mysliveček, J.; Nováková, M.; Palkovits, M.; Križanová, O.; Kvetnanský, R. (2006) Distribution of mRNA and binding sites of adrenoceptors and muscarinic receptors in the rat heart. Life Sci., 2006, 79, 112-120.
15. 3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int. J. Obes., 2002, 26, 1442-1450.
16. Gauthier, C.; Tavernier, G.; Charpentier, F.; Langin, D.; Marec, H. Functional β3-adrenoceptors in human heart. J. Clin. Invest., 1996, 98, 556-562.
17. Gauthier, C.; Tavernier. G.; Trochu.; J.N.; Leblais, V.; Laurent, K.; Langin, D.; Escande, D.; Le Marec, H. Interspecies differences in the cardiac negative inotropic effects ofbeta(3)-adrenoceptor agonists. J. Pharmacol. Exp. Ther., 1999, 290, 687-693.
18. Tavernier, G.; Toumaniantz, G.; Erfanian, M.; Heymannc, M.F.; Laurent, K.; Langina, D.; Gauthier, C. β3-adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice over-expressing the human β-adrenergic receptor. Cardiovasc. Res., 2003, 59, 288-296.
19. Harding, S.E. Lack of evidence for β3-adrenoceptor modulation of contractile function in human ventricular myocytes. Circulation, 1997, 96 (Suppl. I), 1-53.
20. Heubach, J.F.; Rau, T.; Eschenhagen, T.; Ravens, U.; Kaumann, A.J. Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart. Br. J. Pharmacol., 2002, 136(2):217-29.
21. Rozec, B.; Gauthier, C. Beta3-adrenoceptors in the cardiovascular system: putative rules in human pathologies. Pharmacol. Ther., 2006, 111, 652-673.
22. Molenaar, P.; Sarsero, D.; Kaumann, A.J. Proposal for the interaction of non-conventional partial agonists and catecholamines with the "putative β4- adrenoceptor" in mammalian heart. Clin. Exp. Pharmacol. Physiol., 1997, 24, 647-656.
23. Granneman, J.G. The putative β4-adrenergic receptor is a novel state of the β1-adrenergic receptor. Am. J. Physiol., 2001, 43: E199-E202.
24. Santos, I.N.; Sumitame, M.; Caceres, V.M.; Moreira, M.F.; Krieger, M. H.; Spadari-Bratfisch, R.C. Evidence for two atypical conformations of beta-adrenoceptors and their interaction with Gi proteins. Eur. J. Pharmacol., 2005, 513, 109-118.
25. Santos, I.N.; Spadari-Bartfisb, R.C. Chronotropic response to (±)-CGP12177 in right atria of stressed rats. Can. J. Physiol., 2001, 79, 393-399.
26. Mysliveček, J.; Říčný, J.; Kolář, F.; Tuček, S. The effects of hydro-cortisone on the rat heart muscarinic and adrenergic alpha1, beta1 and beta2 receptors, propranolol-resistant binding sites and on some consequent steps in the intracellular signalling. NS Arch. Pharmacol., 2003, 368, 366-376.
27. 1-adrenoceptors: subclassiffcation and functional aspects. In α-Adrenoceptors: Signal Transduction, Ionic Channels, and Effector Organs. Ed. Fujiwara, M., Sugimoto, T. & Kogure, Tokyo: Excerpta Medica, Ltd., 1992, 193-202.
28. 1L) in Bovine Prostate and Rat Heart and Brain. Gen. Pharmac., 1998, 31, 597-600.
29. Ford, A.P.; Daniels, D.V.; Chang, D.J.; Gever, J.R.; Jasper, J.R.; Lesnick, J.D.; Clarke, D.E. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoccptor: implications for alpha1-adrenoceptor classification. Br. J. Pharmacol., 1997, 121, 1127-1135.
30. Marti, D.; Miquel, R.; Ziani, K.; Gisbert, R.; Ivorra, M.D.; Anselmi, E.; Moreno, L.; Villagrasa V.; Barettino, D.; D'Ocon, P. Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, H1923-H1932.
31. Ramsay, D.; Carr, I.C.; Pediani, J.; Lopez-Gimenez, J.F.; Thurlow, R.; Fidock, M.; Milligan, G. High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the alpha1L-adrenoceptor. Mol. Pharmacol., 2004, 66, 228-239.
32. Kenakin, T. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci., 2004, 25, 186-192.
33. Kilts, J.D.; Gerhardt, M.A.; Richardson, M.D.; Sreeram, G.; Mackensen, G.B.; Grocott H.P.; White, W.D.; Davis, R.D.; Newman, M.F.; Reves, J.G.; Schwinn, D.A.; Kwatra, M.M. Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i). Circ. Res., 2000, 87, 705-709.
34. Zhu, W.Z.; Chakir, K.; Zhang, S.; Yang, D.; Lavoie, C.; Bouvier, M.; Hebert, T.E.; Lakatta, E.G.; Cheng, H.; Xiao, R.P. Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ. Res., 2005, 97, 244-251.
35. Morris, A. J.; Malbon, C. C. Physiological regulation of G protein-linked signaling. Physiol. Rev., 1999, 79, 1373-1430.
36. Fukunaga, S.; Setoguchi, S.; Hirasawa, A.; Tsujimoto, G. Monitoring ligand-mediated internalization of G protein-coupled receptor as a novel pharmacological approach. Life Sci., 2006, 80, 17-23.
37. Bünemann, M.; Lee, K.B.; Pals-Rylaarsdam, R.; Roseberry, A.G., Hosey, M.M. Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu. Rev. Physiol., 1999, 61, 169-192.
38. Ferguson, S. S.; Zhang, J., Barak, J. S.; Caron, M. G. Pleiotropic role for GRKS and β-arrestins in receptor regulation. News Physiol. Sci., 1997, 12, 145-151.
39. Tsao, P.; Cao, T.; von Zastrow, M. (2001): Role of endocytosis inmediating downregulation of G-protein-coupled receptors. Trends Pharmacol. Sci., 2001, 22, 91-96.
40. Hunyady, L.; Catt, K.J.; Clark, A.J.; Gáborik, Z. Mechanisms and functions of AT1 angiotensin receptor internalization. Regul. Pept., 2000, 91, 29-44.
41. Liang, W.; Austin, S.; Hoang, Q.; Fishman, P.H. Resistance of the human beta 1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining beta-subtype degradation. J. Biol. Chem., 2003, 278, 39773-39781.
42. Cordeaux, Y.; Hill, S.J. Mechanisms of cross-talk between G-protein-coupled receptors. Neurosignals, 2002, 11, 45-57.
43. Hur, E. M.; Kim, K. T. G. protein-coupled receptor signalling and cross-talk. Achieving rapidity and specificity. Cell Signal., 2002, 14, 397-405.
44. Selbie, L. A.; Hill, S. J. G. protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signaling pathways. Trends Pharmacol. Sci., 1998, 19, 87-93.
45. Watanabe, A. M.; McConnaughey, M. M.; Strawbridge, R. A.; Fleming, J. W.; Jones, L. R.; Besch, H. R. Muscarinic cholinergic receptor modulation of β-adrenergic receptor affinity for catecholamines. J. Biol. Chem., 1978, 253, 4833-4836.
46. Limas, C. J.; Limas, C. Carbachol induces desensitization of cardiac β-adrenergic receptors through muscarinic M1 receptors. Biochem. Biophys. Res. Commun., 1985, 129, 699-704.
47. Paraschos, A.; Karliner, J. S. Receptor crosstalk: effects of prolonged carbachol exposure on beta 1-adrenoceptors and adenylyl cyclase activity in neonatal rat ventricular myocytes. Naunyn Schmiedebergs Arch. Pharmacol., 1994, 350, 267-27.
48. Mysliveček, J.; Trojan, S.; Tuček, S. Biphasic changes of muscarinic and β-adrenergic receptors in rat heart atria during DFP treatment. Life Sci., 1996, 58, 2423-2430.
49. Mysliveček, J.; Lisá, V.; Trojan, S.; Tuček, S. Heterologous regulation of muscarinic and beta-adrenergic receptors in rat cardiomyocytes in culture. Life Sci., 1998, 63, 1169-1182.
50. Reithmann, C.; Werdan, K. Chronic muscarinic cholinoceptor stimulation increases adenylyl cyclase responsiveness in rat cardiomyocytes by a decrease in the level of inhibitory G-protein alpha-subunits. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 351, 27-34.
51. Santos, I.N.; Spadari-Bratfisch, R.C. Stress and cardiac beta adrenoceptors. Stress, 2006, 9, 69-84.
52. Farah, V.M.; Joaquim, L.F.; Morris, M. Stress cardiovascular/autonomic interactions in mice. Physiol Behav., 2006, 89, 569-575.
53. Mysliveček, J.; Říčný, J.; Palkovits, M.: Kvetňanský, R. The Effects Of Short-Term Immobilization Stress On Muscarinic Receptors, β-Adrenoceptors And Adenylyl Cyclase In Different Heart Regions. Ann. N. Y. Acad. Sci., 2004,1018, 315-322.
54. Pelat, M.; Verwaerde, P.; Galitzky, J.; Lafontan, M.; Berlan, M.; Senard, J.M.; Montastruc, J.L. High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs. J. Pharmacol. Exp. Ther., 2003, 304, 246-253.
55. Wang, Z.; Shi, H.; Wang, H. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br. J. Pharmacol., 2004, 142, 395-408.
56. Han, X.; Kobzik, L.; Severson.; D.; Shimoni, Y. Characteristics of nitric oxide-mediated cholinergic modulation of calcium current in rabbit sino-atrial node. J. Physiol., 1998, 509, 741-754.
57. Nathanson, N.M. A multiplicity of muscarinic mechanisms: enough signaling pathways to take your breath away. PNAS, 2000, 97, 6245-6247.
58. Mysliveček, J.; Trojan, S. Mechanisms of G-protein coupled receptor regulation. Sb. Lek., 2000, 101, 205-213.
59. Dhein, S.; van Koppen, C.J.; Brodde, O.E. Muscarinic receptors in the mammalian heart. Pharmacol. Res., 2001, 44, 161-182.
60. Brodde, O.E.; Bruck, H.; Leineweber, K.; Seyfarth, T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res. Cardiol., 2001, 96, 528-538.
61. Pérez, C.C.N.; Tobar, I.D.B.; Jiménez, E.; Darwin Castañeda, D.; Rivero, M.B.; Concepción, J.L.; Chiurillo, M.A.; Bonfante-Cabarcas, R. Kinetic and molecular evidences that human cardiac muscle express non-M2 muscarinic receptor subtypes that are able to interact themselves. Pharmacol. Res., 2006, 54, 345-355.
62. Brown, J.H.; Goldstein, D.; Masters, S.B. The putative M1 muscarinic receptor does not regulate phosphoinositide hydrolysis. Studies with pirenzepine and McN-A343 in chick heart and astrocytoma cells. Mol. Pharmacol., 1985, 27, 525-531.
63. Orellana, S.A.; Brown, J.H. Stimulation of phosphoinositide hydrolysis and inhibition of cyclic AMP formation by muscarinic agonists in developing chick heart. Biochem. Pharmacol., 1985, 34, 1321-1324.
64. Tajima, T.; Tsuji, Y.; Brown, J.H.; Pappano, A.J. Pertussis toxin-insensitive phosphoinositide hydrolysis, membrane depolarization, and positive inotropic effect of carbachol in chick atria. Circ. Res., 1987, 61, 436-445.
65. Tajima, T.; Tsuji, Y.; Sorota, S.; Pappano, A.J. Positive vs. negative inotropic effects of carbachol in avian atrial muscle: role of Ni-like protein. Circ. Res., 1987, 61, 1105-1111.
66. Agnarsson, U.; Tajima, T.; Pappano, A.J. Carbachol depolarizes and accelerates pacemaker activity in the sinoatrial node of chicks treated with pertussis toxin. J. Pharmacol. Exp. Ther., 1988, 147, 150-155.
67. Masters, S.B.; Martin, M.W.; Harden, T.K.; Brown, J.H. Pertussis toxin does not inhibit muscarinic-receptor-mediated phosphoinositide hydrolysis or calcium mobilization. Biochem. J., 1985, 227, 933-937.
68. Brown, J.H.; Goldstein, D. Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in chick heart cells. Mol. Pharmacol., 1986, 30, 566-570.
69. Jones, L.G.; Goldstein, D.; Brown, J.H. Guanine nucleotide-dependent inositol trisphosphate formation in chick heart cells. Circ. Res., 1988, 299-305.
70. Tietje, K.M.; Nathanson, N.M Embryonic chick heart expresses multiple muscarinic acetylcholine receptor subtypes. Isolation and characterization of a gene encoding a novel m2 muscarinic acetylcholine receptor with high affinity for pirenzepine. J. Biol. Chem., 1991, 266, 17382-17387.
71. Mubagwa, K.; Vites, A. M.; Pappano, A.J. Stimulant effects of muscarinic agonists in embryonic chick ventricular muscle. Are the effects mediated by protein kinase C? J. Pharmacol. Exp. Ther., 1992, 260, 1323-1330.
72. Barnett, J.V.; Shamah, S.M.; Lassegue, B.; Griendling, K.K.; Galper, J.B. Muscarinic cholinergic stimulation of inositol phosphate production in cultured embryonic chick atrial cells. Evidence for a role of two guanine-nucleotide-binding proteins. Biochem. J., 1990, 271, 437-442.
73. Brown, S.L.; Brown, J.H. Muscarinic stimulation of phosphatidylinositol metabolism in atria. Mol. Pharmacol., 1983, 24, 351-356.
74. Gurwitz, D.; Sokolovsky, M. Dual pathways in muscarinic receptor stimulation of phosphoinositide hydrolysis. Biochemistry, 1987, 26, 633-638.
75. Moscona Amir, E.; Henis, Y.I.; Sokolovsky, M. Aging of rat heart myocytes disrupts muscarinic receptor coupling that leads to inhibition of cAMP accumulation and alters the pathway of muscarinic-stimulated phosphoinositide hydrolysis. Biochemistry, 1989, 7130-7137.
76. Nadler, E.; Barnea, O.; Vidne, B.; Isakov, A.; Shavit, G. Positive inotropic effect in the heart produced by acetylcholine. J. Basic Clin. Physiol. Pharmacol., 1993, 229-248.
77. Sterin Borda, L.; Echague, A.V.; Leiros, C.P.; Genaro, A.; Borda, E. Endogenous nitric oxide signalling system and the cardiac muscarinic acetylcholine receptor-inotropic response. Br. J. Pharmacol., 1995, 1525-1995.
78. Sun, L.S.; Huber, F.; Robinson, R.B.; Bilezikian, J.P.; Steinberg, S.F.; Vulliemoz, Y. Muscarinic receptor heterogeneity in neonatal rat ventricular myocytes in culture. J. Cardiovasc. Pharmacol., 1996, 27, 455-461.
79. Colecraft, H.M.; Egamino, J.P.; Sharma, V.K.; Sheu, S.S. Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells. J. Biol. Chem., 1998, 73, 32158-32166.
80. Kohl, C.; Schmitz, W.; Scholz, H. Positive inotropic effect of carbachol and inositol phosphate levels in mammalian atria after pretreatment with pertussis toxin. J. Pharmacol. Exp. Ther., 1990, 254, 894-899.
81. Ford, A.P.D.W.; Eglen, R.M.; Whiting, R.L. Analysis of muscarinic cholinoceptors mediating phosphoinositide hydrolysis in guinea pig cardiac muscle. Eur. J. Pharmacol. Mol. Pharmacol. Section, 1992, 225, 105-112.
82. Gallo, M.P.; Alloatti, G.; Carola, E.; Oberto, A.; Cesare Levi, R. M-1 muscarinic receptors increase calcium current and phosphoinositide turnover in guinea-pig ventricular cardiocytes. J. Physiol., 1993, 471, 41-60.
83. Yang, C.M.; Yeh, M.M.; Sung, T.C.; Chen, F.F.; Wang, Y.Y. Characterization of muscarinic receptor subtypes in canine left ventricular membranes. J. Recept. Res., 1992, 12, p., 427-449.
84. Shi, H.; Wang, H.; Wang, Z. M3 muscarinic receptor activation of a delayed rectifier potassium current in canine atrial myocytes. Life Sci., 1999, 64, PL251-PL2457.
85. Birk, E.; Riemer, R.K. Myocardial cholinergic signaling changes with age. Pediatr. Res., 1992, 31, 601-605.
86. Deighton, N.M.; Motomura, S.; Borquez, D.; Zerkowski, H.R.; Doetsch, N.; Brodde, O.E Muscarinic cholinoceptors in the human heart: Demonstration, subclassification, and distribution. Naunyn Schmiedebergs Arch. Pharmacol., 1990, 341, 14-21.
87. Du X.Y., Schoemaker R.G., Bos E., Saxena P.R. Different pharmacological responses of atrium and ventricle: studies with human cardiac tissue. Eur. J. Pharmacol., 1994, 259, 173-180.
88. Du, X.Y.; Schoemaker, R.G., Bos, E.; Saxena; P.R. Characterization of the positive and negative inotropic effects of acetylcholine in the human myocardium. Eur. J. Pharmacol., 1995, 284, 119-127.
89. Giessler, C.; Wangemann, T.; Zerkowski, H.R.; Brodde, O.E. Age-dependent decrease in the negative inotropic effect of carbachol on isolated human right atrium. Eur. J. Pharmacol., 1998, 357, 199-202.
90. Jerusalinsky, D.; Kornisiuk, E.; Alfaro, P.; Quillfeldt, J.; Ferreira, A.; Rial, V.E.; Duran, R.; Cervenansky, C. Muscarinic toxins: novel pharmacological tools for the muscarinic cholinergic system. Toxicon, 2000, 38, 747-761.
91. Bradley, K.N.; Rowan, E.G.; Harvey, A.L. Effects of muscarinic toxins MT2 and MT7, from green mamba venom, on m1, m3 and m5 muscarinic receptors expressed in Chinese Hamster Ovary cells. Toxicon, 2003, 41, 207-215.
92. Mourier, G.; Dutertre, S.; Fruchart-Gaillard, C.; Menez, A.; Servent, D. Chemical synthesis of MT1 and MT7 muscarinic toxins: critical role of Arg-34 in their interaction with M1 muscarinic receptor. Mol. Pharmacol., 2003, 63, 26-35.
93. Nasman, J.; Jolkkonen, M.; Ammoun, S.; Karlsson, E.; Akerman, K.E. Recombinant expression of a selective blocker of M1 muscarinic receptors. Biochem. Biophys. Res. Commun., 2000, 271, 435-439.
94. Bohme, T.M.; Augelli-Szafran, C.E.; Hallak, H.; Pugsley, T.; Serpa, K.; Schwarz, R.D. Synthesis and pharmacology of benzoxazines as highly selective antagonists at M4 muscarinic receptors. J. Med. Chem., 2002, 45, 3094-3102.
95. Wang, Z.; Shi, H.; Wang, H. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br. J. Pharmacol., 2004, 142, 395-408.
96. Yang, C.M.; Chen, F.F.; Sung, T.C.; Hsu, H.F.; Wu, D. Pharmacological characterization of muscarinic receptors in neonatal rat cardiomyocytes. Am. J. Physiol., 1993, 265, C666-C673.
97. Brown, S.L.; Brown, J.H. Muscarinic stimulation of phosphatidylinositol metabolism in atria. Mol. Pharmacol., 1983, 24, 351-356.
98. Gomeza, J.; Shannon, H.; Kostenis, E.; Felder, C.; Zhang, L.; Brodkin, J.; Grinberg, A.; Sheng, H.; Wess, J. Pronounced pharmacologic deficits in M2 muscarinic acetyl-choline receptor knock out mice. Proc. Natl. Acad. Sci. USA, 1999, 96, 1692-1697.
99. Ponicke, K.; Heinroth-Hoffmann, I.; Brodde, O.E. Demonstration of functional M3-muscarinic receptors in ventricular cardiomyocytes of adult rats. Br. J. Pharmacol., 2003, 138, 156-160.
100. Hellgren, I.; Mustafa, A.; Riazi, M.; Suliman, I.; Sylven, C.; Adem, A. Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol. Life Sci., 2000, 20, 175-80.
101. Wang, H.; Han, H.; Zhang, L.; Shi, H.; Schram, G.; Nattel, S.; Wang, Z.; Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol. Pharmacol., 2001, 59, 1029-1036.
102. Borda, E.S.; Leiros, C.P.; Camusso, J.J.; Bacman, S.; Sterin Borda, L. Differential cholinoceptor subtype-dependent activation of signal transduction pathways in neonatal versus adult rat atria. Biochem. Pharmacol., 1997, 53, 959-967.
103. Camusso, J.J.; Sterin Borda, L.; Rodriguez, M.; Bacman Borda, E. Pharmacological evidence for the existance of different subtypes of muscarinic acetylcholine receptors for pbosphoinositide hydrolysis in neonatal versus adult rat atria. J. Lipid Med. Cell Signal., 1995, 12, 1-10.
104. Barnett, J.V.; Shamah, S.M.; Lassegue, B.; Griendling, K.K.; Galper, J.B. Muscarinic cholinergic stimulation of inositol phosphate production in cultured embryonic chick atrial cells. Evidence for a role of two guanine-nucleotide-binding proteins. Biochem. J., 1990, 271, 437-442.
105. Mysliveček, J.; Trojan, S. Regulation of β-adrenoceptors and muscarinic receptors in the heart. Gen. Physiol. Biohys., 2003, 22, 3-14.
106. Rosenberger, L.B.; Yamamura, H.I.; Roeske, W.R. The regulation of cardiac muscarinic cholinergic receptors by isoproterenol. Eur. J. Pharmacol., 1980, 65, 129-130.
107. Nomura, Y.; Kajiyama, H.; Segawa, T. Alteration in sensitivity to isoproterenol and acetylcholine in the rat heart after repeated administration of isoproterenol. J. Pharmacol. Exp. Ther., 1982, 220, 411-416.
108. Garofolo, M. C.; Seidler, J.F.; Auman, J. T.; Slotkin, T. A. β-adrenergic modulation of muscarinic cholinergic receptor expression and function in developing heart. Am. J. Physiol. Regul. Integr., 2002, 282, R1356-1363.
109. Matthews, J. M.; Falckh, H. J.; Molenaar, P.; Summers, R. J. Chronic (-)isoprenaline infusion down-regulates β1- and β2-adrenoceptors but does not transregulate muscarinic cholinoceptors in rat heart. Naunyn Schmiedebergs Arch. Pharmacol., 1996, 353, 213-225.
110. Jackson, D. A.; Nathanson, N. M. Subtype-specific regulation of muscarinic receptor expression and function by heterologous receptor activation. J. Biol. Chem., 1995, 270, 22374-22377.
111. Reithmann, C.; Panzner, B.; Werdan, K. Distinct pathways for beta-adrenoceptor-induced up-regulation of muscarinic acetylcholine receptors and inhibitory G-protein alpha-subunits in chicken cardiomyocytes. Naunyn Schmiedebergs Arch. Pharmacol., 1992, 345, 530-540.
112. Lee, N. H.; Fraser, C.M. Cross-talk between ml muscarinic acetylcholine and β2-adrenergic receptors. J. Biol. Chem., 1993, 268, 7949-7957.
113. Farah, V.M.A.; Joaquim, L.F.; Morris, M. Stress cardiovascular/autonomic interactions in mice. Physiol. Behav., 2006, 89, 569-75.
114. Nováková, M.; Tillinger, A.; Kubovčáková, L.; Kvetňský, R.; Mysliveček., J. Balance between muscarinic receptors and adrenoceptors in animals exposed to stress. Ann. N. Y. Acad Sci., 2008 (in press).
115. Bylund, D.B.; Eikenberg, D.C.; Hieble, J.P.; Langer, S.Z.; Lefkowitz, R.J.; Minneman, K.P.; Molinoff, P.B.; Ruffolo, R.R.J.R.; Trendelenburg, U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev., 1994, 46, 121-136.
116. Chen, X.H.; Harden, K.T.; Nicholas, R.A. Molecular Cloning and Characterization of a Novel β-Adrenergic Receptor. J. Biol. Chem., 1994, 269, 24810-24819.
117. Skeberdis, V.A. Structure and function of β3-adrenergic receptors. Medicina (Kaunas), 2004, 40, 407-414.
118. IUPHAR receptor database (http://www.iuphar-db.org/GPCR/; Ki)
119. Caulfield, M.P.; Birdsal, N.J.M. International Union of Pharmacology. XVII. Classification of muscarinic acetlycholine receptors. Pharmacol Rev., 1998, 50, 279-290.
120. Doods, H.N.; Entzeroth, M.; Ziegler, H.; Mayer, N.; Holzer, P. Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur. J. Pharmacol., 1994, 253, 275-281.
121. Eglen, R.M.; Nahorski, S.R. The muscarinic M(5) receptor: a silent or emerging subtype? Br. J. Pharmacol., 2000, 130, 13-21
122. Choppin, A.; Stepan, G.J.; Loury, D.N.; Watson, N.; Eglen, R.M. Characterization of the muscarinic receptor in isolated uterus of sham operated and ovariectomized rats. Br. J. Pharmacol., 1999, 127, 1551-1558.
123. Lazareno, S.; Gharagozloo, P.; Kuonen, D.; Popham, A.; Birdsall, N. J. Subtype-Selective Positive Cooperative Interactions Between Brucine Analogues and Acetylcholine at Muscarinic Receptors: Radioligand Binding Studies. Mol. Pharmacol., 1998, 53, 573-589.
124. Bolognesi, M.L.; Minarini, A.; Budriesi, R.; Cacciaguerra, S.; Chiarini, A.; Spampinato, S.; Tumiatti, V.; Melchiorre; C. Universal Template Aroach to Drug Design: Polyamines As Selective Muscarinic Receptor Antagonists. J. Med. Chem., 1989, 41, 4150-4160.
125. Buckley N. J., Hulme E. C., and Birdsall N. J. Use of clonal cell lines in the analysis of neurotransmitter receptor mechanisms and function. Biochim. Biophys. Acta, 1990, 1055, 43-53.
126. Bolden, C.; Cusack, B.; Richelson, E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther., 1992, 260, 576-580.
127. Lazareno, S.; Buckley, N.J.; Roberts, F. F. Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol. Pharmacol., 1990, 38, 805-815.